Credits: Pexels
As you grow old, your health starts to deteriorate. Everything, whether it is your mental health or your physical health, starts to slow down. However, with age, your mental health gets overshadowed by your physical health.
If you note these signs in your ageing parents or grandparents, take note of it. Try to get involved with them. It is also important to ensure that they have a separate social circle apart from the family. This way, they can have friends who they can also relate to.
With age, suggests Sinha, you are more prone to be depressed, and anxious. “Mental health conditions like schizophrenia or bipolar disorders are not something that happens when you grow older. You may have been living with these for the last 40 years, but the management differs, she suggests.
As you grow old, your symptoms start to overlap with other mental health conditions. For the proper treatment professionals use differential diagnosis, suggests Sinha. “The lines become blurred and to differentiate the symptoms from one mental health condition to another becomes difficult,” she says.
There are also food habits like eating leafy vegetables, nuts, fish, virgin coconut and beans that help with brain functions.
Sinha suggests that keeping a social circle and continuing your hobbies can help your mind stay healthy. “Men especially face this issue, after they retire, they feel like they are at the loss of authority, and they start to lose control. It is thus important to keep doing things and learning a new skill to keep your brain active. While for women, since they continue taking care of the house, their brain stays active,” she says.
Cognitive stimulation is the key, especially to managing dementia, she notes.
“Just with weight training, you push your body and after a while, it becomes your muscle memory. Same with the brain. However, one should not get into solving too many puzzles, or trivia after being diagnosed with dementia. Because that would mean you are making your already injured brain exercise which might lead to agitation,” she recommends.
“The most important part is for the caregiver to understand what is happening and come to terms with the conditions. Because the elderly with cognitive conditions are not able to understand, they cannot be told or instructed to do anything. Thus, the responsibility is solely on the caregiver,” points out Sinha.
So, what can be done?
Reach out to therapists and counsellors to know the ways to create such a healthy environment.
She suggests adopting the same approach that you do with kids and with your pets. This is when you focus on gestures, body language and mood over language. Due to cognitive disorders, parents experience a loss of language and the only way to communicate and to understand what they are communicating is through these means.
Create a healthy environment by agreeing with them and listening to their stories. The responsibility of creating a safe environment is totally with you.
There might be times when your parents may do socially unacceptable or non-compliance behaviour. But it is important to understand the triggers and ensure that the triggers do not occur anymore.
Credit: Canva
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, affects millions of people worldwide. The lifelong condition commonly begins in adolescence or early adulthood and can require repeated hospital treatment, long-term immunosuppressive medication, and, in some cases, surgery.
Despite advances in treatment, many patients cycle through multiple therapies without achieving lasting disease control, impacting their lives and costing healthcare systems millions.
Now, a team of UK researchers from the Universities of Oxford, Newcastle, and Cambridge has identified an important driver of inflammatory bowel disease (IBD).
The findings, published in the New England Journal of Medicine, suggest that inflammatory bowel disease is not a single condition but a group of biologically distinct diseases driven by different underlying mechanisms.
"Understanding what drives the inflammation provides a clear explanation for disease in this group of people and opens the door to new treatments that target the autoantibodies themselves or cells that produce those autoantibodies," said Professor Holm Uhlig, a pediatric gastroenterologist and director of the Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford.
Also read: Alcohol Study Shelved By Trump Administration Published In Scientific Journal: What Did It Find?
The researchers analyzed more than 4,900 patients with IBD and discovered that:
Antibodies that block interleukin-10 (IL-10), a cell-to-cell messenger that normally acts as one of the body's key controls on inflammation, effectively remove the immune system's natural "brake" on inflammation, allowing inflammatory responses to continue unchecked.
The researchers found high levels of anti-IL-10 neutralizing autoantibodies in the blood of about 3.5% of IBD patients, including those with Crohn's disease and ulcerative colitis, but not in healthy individuals. This could equate to 15,000–20,000 people with IBD in the UK carrying these autoantibodies.
Read More: US FDA Approves First New Sunscreen Ingredient Since the 1990s
The researchers also found that the presence of these antibodies was strongly linked to carriage of a particular genetic variant known as HLA-DRB1*01:03.
The link between HLA-DRB1*01:03 and a severe form of inflammatory bowel disease was first identified by Oxford researchers 30 years ago.
The new findings show that people carrying this variant are far more likely to develop antibodies that block IL-10, helping explain how the gene contributes to disease.
The researchers say the findings support the development of a blood test to identify this subgroup of patients, helping clinicians move quickly toward more appropriate treatment.
As per the Centers for Disease Control and Prevention (CDC), IBD refers to a group of lifelong diseases that affect your intestines. The main types of IBD are ulcerative colitis and Crohn's disease.
Ulcerative colitis affects the large intestine, while Crohn’s disease can inflame any part of the digestive tract. Both are lifelong conditions of unknown cause that trigger abdominal pain, diarrhea and other complications, with no known cure.
Credit: Canva
With modern lifestyle changes, delayed childbearing, and other factors, infertility among Indians as young as 25 has become a looming public health concern for the country. However, the issue does not stop at the present.
A recent study published by The Menopause Society in their journal Menopause found that infertility may lead to earlier menopause, raising questions about the long-term reproductive health implications of this demographic shift.
Menopause is the final stage of a woman’s reproductive lifecycle, when menstruation stops, and she can no longer get pregnant. When the ovaries stop producing estrogen and progesterone, and a woman misses her period for 12 consecutive months, she has officially reached menopause.
Although menopause is a regular part of ageing, women typically reach menopause between 45 and 55 years of age. If menopause occurs before age 45, it is considered early menopause. If it occurs before 40, it is termed premature menopause – rarer than early menopause but involves the same causes, symptoms, and health risks.
While previous studies have been conducted to find a link between infertility and both early and premature menopause, they have had mixed results and did not consider the effect of different types of infertility; this study focuses on women with a history of primary infertility, women who have never achieved pregnancy, and have difficulty conceiving.
For the study, researchers examined the reproductive lifecycle of nearly 700 women in the U.S. – 461 with primary infertility and 530 without infertility – who were otherwise demographically similar (age, education, smoking status, etc.). It found that the 461 women had a 25% higher likelihood of reaching natural menopause about 1.2 years earlier than the 530.
Researchers also noted that women with underlying endometriosis as a cause of their infertility reached menopause between 40 and 44 years, much sooner than the national average of the United States, i.e., 52 years.
Possible explanations include accelerated ovarian ageing, reduced ovarian reserve, or the effects of endometriosis on ovarian function. But no matter the causes, the implications for women’s long-term health are substantial.
All women are born with a finite, predetermined number of eggs, which are sensitive to age, environmental toxins, medications, hormonal imbalances, and lifestyle factors. When exposed to such risk factors, especially over a long period of time, the DNA inside the eggs is altered, causing permanent genetic damage and reducing the egg quality and quantity.
As a core part of the reproductive process, any damage to the eggs directly affects reproductive health and, in turn, long-term systemic health.
Infertility impacts more than the ability to conceive and go through a pregnancy; it is often a sign of underlying health conditions and potential chronic illnesses, acting as a biomarker of increased all-cause mortality. Experiencing infertility itself increases a woman’s risk of developing cardiovascular disease, metabolic disorders, gynecologic cancers, etc., but reaching menopause early on top of that puts them at further health risk, adding osteoporosis and cognitive decline to the mix, along with the emotional distress and mental health challenges.
Indian women already reach menopause earlier than women in Western countries, with the average woman experiencing menopause at 46.2 years of age. With fertility rates dropping across the country, this study highlights just how critical it is to increase fertility awareness. Early screenings and regular fertility testing can help detect risks early and enable timely intervention, not only to combat the ongoing crisis but to ensure that women live healthy, fulfilling lives without impending morbidity.
Credit: AI Generated Image
A new oral GLP-1 medication has delivered encouraging results in a Phase 2b clinical trial for people living with type 2 diabetes.
According to AstraZeneca, its experimental tablet, elecoglipron, significantly lowered blood sugar levels and helped participants lose an average of 10.5% of their body weight after 26 weeks of treatment.
The findings were presented at the 2026 American Diabetes Association Scientific Sessions in New Orleans and published in The Lancet on June 8.
Elecoglipron joins a growing wave of GLP-1 therapies being developed as pills, offering an alternative to injectable drugs such as Ozempic, Wegovy, Zepbound, and Mounjaro.
The first oral GLP-1 treatment, Rybelsus from Novo Nordisk, received FDA approval in 2019 for adults with type 2 diabetes. Since then, oral options have continued to expand. In December 2025, the FDA approved a tablet version of Wegovy for weight management, while Eli Lilly’s oral obesity treatment, Foundayo, gained approval in April.
Independent experts say AstraZeneca’s results highlight the growing potential of non-injectable GLP-1 therapies for both diabetes and obesity treatment.
“It’s encouraging to see another oral medication demonstrating the benefits of GLP-1 therapy without requiring injections,” said Dr. Pouya Shafipour, a family and obesity medicine specialist at Providence Saint John’s Health Center in California.
Dr. Marilyn Tan, an endocrinologist and professor of medicine at Stanford University, noted that the rapidly expanding GLP-1 market could soon welcome another oral treatment option if elecoglipron succeeds in Phase 3 trials and ultimately secures FDA approval.
GLP-1 is a natural hormone produced in the intestines that regulates blood sugar, appetite, and digestion. Now, every time you eat, your body produces various hormones, including GLP-1. These are called post-nutrition hormones, and they help you absorb the energy you just consumed.
GLP-1 travels to your pancreas, prompting it to produce insulin. It also travels to the hypothalamus in your brain, which gives you the feeling of being full or satiated. GLP-1 pills imitate that hormone, thereby silencing the food chatter in the brain. Interestingly, for some people, this food chatter is really quiet, and for others it is an outburst. So with GLP-1, silencing this self-talk in the brain, people tend to lose their appetite and eventually weight.
However, it is important to note that losing weight includes not just fat but muscle as well. Losing too much muscle can lead to reduced strength and a shorter life span. Notably, records show that most people who start taking them stop them at 12 weeks; therefore, it is important for some but not for others.
The side effects of these pills include:
© 2024 Bennett, Coleman & Company Limited